NeonMind

NeonMind is a leader in psilocybin-based treatments for obesity and is developing the first and only novel psilocybin-based drug candidate for obesity. NeonMind's lead candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybin combined with psychotherapy to achieve lasting weight loss for patients with obesity. NeonMind also has an additional pipeline opportunity, NEO-002, which uses low-dose psilocybin to control appetite. NeonMind also sees opportunities to provide integrated mental health services and offer evidence-supported innovative therapies based on local market needs.